Key highlights
- Nefecon is marketed in the U.S. as TARPEYO® (budesonide) delayed release capsules.
- KDIGO 2025 guidelines focus on IgAN and IgAV management.
- The guidelines aim to standardize care and improve outcomes for IgAN.
Overview
Asahi Kasei announced the inclusion of Nefecon, marketed in the U.S. as TARPEYO® (budesonide) delayed release capsules, in the KDIGO 2025 Clinical Practice Guideline. This guideline focuses on the management of IgA Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).
Guideline Significance
The KDIGO 2025 guideline aims to standardize care and improve outcomes by providing evidence-based recommendations for IgAN diagnosis, prognosis, and treatment. It is recognized as the global standard for nephrology practice, influencing treatment decisions for IgAN patients.
